​

Relmada Therapeutics Ownership | Who Owns Relmada Therapeutics?

OverviewForecastFinancialsChartTranscripts

Relmada Therapeutics Ownership Summary

Relmada Therapeutics is owned by 23.32% institutional investors, 10.75% insiders, and 65.93% retail investors. Ikarian capital is the largest institutional shareholder, holding 5.55% of RLMD shares. Vanguard US Total Market Shares ETF is the top mutual fund, with 2.57% of its assets in Relmada Therapeutics shares.

RLMD Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockRelmada Therapeutics23.32%10.75%65.93%
SectorHealthcare Stocks 42.50%10.81%46.69%
IndustryBiotech Stocks 45.24%10.75%44.01%
IdeaPsychedelic Stocks List31.75%11.99%56.26%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Ikarian capital1.84M5.55%$3.70M
Driehaus capital management740.01K2.23%$1.49M
Boothbay fund management693.24K2.09%$1.39M
Blackrock573.31K1.90%$1.72M
Acadian asset management582.54K1.76%$1.17M
Blackrock funding, inc. /de508.00K1.53%$1.02M
Vanguard group418.58K1.26%$841.35K
Advisorshares investments403.49K1.22%$811.01K
Geode capital management296.21K0.89%$595.53K
Marshall wace, llp272.05K0.82%$546.83K

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Ikarian capital1.84M0.37%$3.70M
Advisorshares investments403.49K0.13%$811.01K
Apricus wealth47.46K0.05%$95.40K
Spotlight asset group20.00K0.04%$60.00K
Pandora wealth20.00K0.02%$40.20K
Boothbay fund management693.24K0.02%$1.39M
Parsons capital management inc/ri163.34K0.02%$328.31K
Rbf capital163.26K0.01%$328.15K
Driehaus capital management740.01K0.01%$1.49M
Mgo one seven100.00K0.00%$201.00K

Top Buyers

HolderShares% AssetsChange
Ikarian capital1.84M0.37%1.80M
Boothbay fund management693.24K0.02%693.24K
Marshall wace, llp272.05K0.00%117.48K
Two sigma investments, lp173.61K0.00%78.20K
Vanguard group418.58K-54.50K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---674.83K
Palo alto investors lp---495.15K
Vestal point capital, lp---490.00K
Opaleye management---480.00K
Millennium management64.36K0.00%-277.09K

New Positions

HolderShares% AssetsChangeValue
Boothbay fund management693.24K0.02%693.24K$1.39M
Barclays10.00K-10.00K$20.10K
Farther finance advisors838.00-838.00$1.68K

Sold Out

HolderChange
Blackston financial advisory group-2.00
Innealta capital-5.00
Smartleaf asset management-35.00
Qube research-56.00
Larson financial group-100.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 202544-8.33%7,739,57845.94%239.13%16-5.88%10-23.08%
Jun 30, 2025476.82%5,303,149-14.73%153.82%1741.67%12-14.29%
Mar 31, 202544-15.38%6,219,493-25.95%202.64%12-36.84%14-33.33%
Dec 31, 202420-73.68%5,351,011-56.77%171.05%6-70.00%8-68.00%
Sep 30, 202476-9.52%12,376,687-8.70%412.03%20-4.76%25-21.88%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard US Total Market Shares ETF851.92K2.57%-
Vanguard Total Stock Mkt Idx Inv803.29K2.42%-48.63K
Franklin Biotechnology Discv A(acc)USD623.80K2.07%-221.90K
AdvisorShares Psychedelics ETF425.60K1.28%-
Franklin Biotechnology Discovery A336.31K1.11%-120.09K
Vanguard Institutional Extnd Mkt Idx Tr256.25K0.77%-97.37K
Horizons Psychedelic Stock ETF227.04K0.75%-36.13K
Fidelity Extended Market Index158.75K0.48%564.00
Bridgeway Ultra-Small Company100.18K0.33%-
Fidelity Enhanced Small Cap ETF92.92K0.31%1.75K

Recent Insider Transactions

DateNameRoleActivityValue
Nov 05, 2025Shenouda Maged Chief Financial OfficerBuy$1.10M
Nov 05, 2025Ence Chuck CAO and COOBuy$299.20K
Nov 05, 2025TRAVERSA SERGIO Chief Executive OfficerBuy$599.50K
Nov 05, 2025Kelly Paul Edward Chief Operating OfficerBuy$198.00K
Aug 26, 2025TRAVERSA SERGIO Chief Executive OfficerBuy$49.94K

Insider Transactions Trends

DateBuySell
2025 Q44-
2025 Q33-
2025 Q28-
2024 Q4--
2024 Q38-

RLMD Ownership FAQ

Who Owns Relmada Therapeutics?

Relmada Therapeutics shareholders are primarily institutional investors at 23.32%, followed by 10.75% insiders and 65.93% retail investors. The average institutional ownership in Relmada Therapeutics's industry, Biotech Stocks , is 45.24%, which Relmada Therapeutics falls below.

Who owns the most shares of Relmada Therapeutics?

Relmada Therapeutics’s largest shareholders are Ikarian capital (1.84M shares, 5.55%), Driehaus capital management (740.01K shares, 2.23%), and Boothbay fund management (693.24K shares, 2.09%). Together, they hold 9.87% of Relmada Therapeutics’s total shares outstanding.

Does Blackrock own Relmada Therapeutics?

Yes, BlackRock owns 1.90% of Relmada Therapeutics, totaling 573.31K shares as of Jun 2024. This represents 0% of BlackRock's total assets, with a market value of 1.72M$. In the last quarter, BlackRock decreased its holdings by -4.874K shares, a -0.84% change.

Who is Relmada Therapeutics’s biggest shareholder by percentage of total assets invested?

Ikarian capital is Relmada Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.37% of its assets in 1.84M Relmada Therapeutics shares, valued at 3.7M$.

Who is the top mutual fund holder of Relmada Therapeutics shares?

Vanguard US Total Market Shares ETF is the top mutual fund holder of Relmada Therapeutics shares, with 2.57% of its total shares outstanding invested in 851.92K Relmada Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools